ARTV
Artiva Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.19
+0.58%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -15.6%
- EBIT
- -17.9%
- EPS
- +3.8%
- Free cash flow
- -38.5%
- Operating cash flow
- -39.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +5.2%
- EPS
- +27.5%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- -45.0%
- EBIT
- -34.7%
- Net income
- -43.4%
- EPS
- +34.0%
- Free cash flow
- -42.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026